Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5270523 | 0.89 | ADRA1B (0.54) | SLC6A4SIGMAR1DRD3HTR1A | |
| SCHEMBL5264311 | 0.86 | ADRA1D (0.53) | DRD2DRD4HTR1A | |
| SCHEMBL5264783 | 0.86 | DRD2 (0.51) | SLC6A2SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL5270524 | 0.83 | MEN1 (0.54) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL5316188 | 0.81 | HTR1A (0.44) | SIGMAR1HTR1AHTR7 | |
| SCHEMBL5263941 | 0.81 | MEN1 (0.57) | SLC6A4DRD2HTR1AHTR7 | |
| SCHEMBL5265422 | 0.81 | ADRA1D (0.57) | DRD2DRD3HTR1AHTR7 | |
| SCHEMBL5268778 | 0.81 | MEN1 (0.48) | SIGMAR1DRD2DRD4HTR1AHTR7 | |
| SCHEMBL5265038 | 0.81 | OPRM1 (0.54) | SIGMAR1DRD2DRD4DRD3HTR1A | |
| SCHEMBL5268003 | 0.81 | SIGMAR1 (0.53) | SIGMAR1HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |